Prevention and treatment of cardiovascular disease in women: the obstetric-gynecologist's point of view.

about

Impact of menopause and diabetes on atherogenic lipid profile: is it worth to analyse lipoprotein subfractions to assess cardiovascular risk in women?Racial and Ethnic Disparities in Cardiovascular Disease: An Assessment of Obstetrician-Gynecologists' Knowledge, Attitudes, and Practice Patterns.

P2860

Q30234825-0D85DBFA-7860-47E8-ABB2-97A6A0C5D7BE Q40007867-3EACC2DD-EEBD-4653-97DA-DA6A98F0CF95

P2860

Prevention and treatment of cardiovascular disease in women: the obstetric-gynecologist's point of view.

Item

http://www.wikidata.org/entity/Q38095646

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Prevention and treatment of ca ...... -gynecologist's point of view.

@en

type

Item

label

Prevention and treatment of ca ...... -gynecologist's point of view.

@en

prefLabel

Prevention and treatment of ca ...... -gynecologist's point of view.

@en

P1476

Prevention and treatment of ca ...... c-gynecologist's point of view

@en

P2093

Roberto Brunelli

http://www.w3.org/2001/XMLSchema#string

P2860

Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

Raising the priority of preventing chronic diseases: a political process.

Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study

Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial.

The 2012 hormone therapy position statement of: The North American Menopause Society.

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond.

Recommendations for the use of LDL apheresis.

P304

162-168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1744-9987.12022

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppina Perrone

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23551672

http://www.w3.org/2001/XMLSchema#string

Prevention and treatment of cardiovascular disease in women: the obstetric-gynecologist's point of view.

about

P2860

P2860

Prevention and treatment of cardiovascular disease in women: the obstetric-gynecologist's point of view.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698